uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
Show others and affiliations
2008 (English)In: Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, E-ISSN 1099-1557, Vol. 17, no 1, 90-102 p.Article in journal (Refereed) Published
Abstract [en]

Purpose To evaluate the value of a registry, set in 'real-life practice', as a contribution to evidence-based medicine and to estimate the impact of information collected in such a registry, on the up to date knowledge in growth hormone (GH)-related disorders. Methods Analysis of data collected prospectively for a pharmacoepidemiological registry-KIMS (Pfizer International Metabolic Database)-in assessing long-term clinical and safety outcomes of GH treatment (Genotropin (R)) in patients with GH deficiency. The study was based on 11374 treated (40000 patient-years of observation) and 263 untreated adult GH deficient patients from 30 countries, in whom background characteristics, clinical values such as lipids and body composition, quality of life (QoL) and GH dosage as well as safety profile were evaluated. Citation analysis for the published papers was also performed. Results The study depicts the clinical picture of adult patients with GH deficiency managed in current clinical settings. It confirms the features previously detected such as increased cardiovascular risk, mostly dyslipidemia and abnormal body composition as well as impaired QoL. There was considerable heterogeneity of conditions resulting in GH deficiency. The large database also enabled study of rare causes of the condition. The 31 out of 36 KIMS papers were cited 544 times, in 125 different journals. Conclusions These findings and the further insight into the response to GH replacement therapy show that the registry methodology is valuable for filling the gaps of information in evidence-based medicine that cannot be addressed by clinical trials.

Place, publisher, year, edition, pages
2008. Vol. 17, no 1, 90-102 p.
Keyword [en]
growth hormone deficiency in adults, hypopituitarism, safety, treatment outcome, pharmacoepidemiology, survey
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-13180DOI: 10.1002/pds.1510ISI: 000252535300012PubMedID: 17957812OAI: oai:DiVA.org:uu-13180DiVA: diva2:40950
Available from: 2008-01-21 Created: 2008-01-21 Last updated: 2017-12-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Pharmacy
In the same journal
Pharmacoepidemiology and Drug Safety
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 414 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf